Alaunos Therapeutics Inc. 2026年季度报告

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements as defined in the Private SecuritiesLitigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Quarterly Report thatare not historical fact, and in some cases can be identified by terms such as: “anticipate,” “believe,” “estimate,” “expect,” These statements are based on management’s current beliefs and assumptions and on information currently available tomanagement. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity,performance or achievements to be materially different from the information expressed or implied by these forward-lookingstatements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you •our ability to raise substantial additional capital to continue as a going concern and fund our planned operations;•our ability to successfully advance our preclinical Obesity and Metabolic Disorders Program, including ALN1003,through additional studies, formulation optimization, and manufacturing scale-up for progressing toward IND-enablingactivities;•our ability to enter into partnerships, collaborations or licensing arrangements to support development of our Obesityand Metabolic Disorders Program;•estimates regarding our expenses, use of cash, cash runway, timing of future cash needs and anticipated capital Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or toour future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actualresults, level of activity, performance or achievements to be materially different from any future results, level of activity,performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results,levels of activity or performance of achievements to differ materially from current expectations include, among other things, those Unless the context requires otherwise, references in this Quarterly Report to “Alaunos,” the “Company,” “we,” “us” or “our” refer We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business,including our corporate name, logos and website names. We own the Alaunos® and hunTR® trademarks as well as the graphictrademark found on our website. Other trademarks, service marks and trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names SUMMARY OF SELECTED RISKS ASSOCIATED WITH OUR BUSINESS Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition,results of operations, cash flows and prospects could be materially and adversely affected. You should carefully review andconsider the full discussion of our risk factors in the section titled “Risk Factors” in Part I, Item 1A of our Annual Report, filed with •We require substantial additional financial resources to continue as a going concern and advance our Obesity andMetabolic Disorders Program; the failure to obtain it on acceptable terms would materially harm our business.•Our strategic reprioritization to progress our Obesity and Metabolic Disorders Program may not be successful, may notyield the desired results and we may be unsuccessful in identifying and implementing any alternate strategictransaction.•Our cash resources are limited. As of March 31, 2026, we had approximately $0.35 million of cash and cashequivalents. At our current rate of spending, we expect our cash to be sufficient to fund operations only into the secondquarter of 2026.•On April 9, 2026, we received a notice from Nasdaq that we are not in compliance with the minimum stockholders’equity requirement ($2.5 million) under Nasdaq Listing Rule 5550(b)(1). There can be no assurance that ourcompliance plan will be accepted or that we will regain compliance within any extension period granted by Nasdaq.Delisting could materially adversely affect our stock price, liquidity, and ability to raise capital.•If we are unable to progress our Obesity and Metabolic Disorders Program, our Board of Directors may decide topursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholderswill depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved forcommitments and contingent liabilities.•Our stock price has been, and may continue to be, volatile.•We have identified a material weakness and failed to maintain an effective internal control environment, which mayresult in material misstatement